AbbVie is planning a $380 million expansion of its headquarters campus in North Chicago, Ill. Construction will begin in spring of 2026 on two plants for the production of active pharmaceutical ingredients (APIs). Enabling the creation of innovative treatments for neurological conditions and obesity, the next-generation facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to maximize purity, efficacy, and operational efficiency. Full production is expected to commence in 2029. The two centers will support approximately 300 new full-time jobs, including positions for engineers, scientists, manufacturing operators, and lab technicians.
The project is part of Abbvie's $100 billion commitment to increase its research, development, and manufacturing capacity in the United States over the next decade. Ground was broken in September 2025 on a $195 million chemical synthesis facility in North Chicago that will relocate API production for select immunology, neurology, and oncology products from Europe and Asia to the U.S. The company will receive $25 million in tax credits over 15 years for the three facilities as part of the state's Economic Development for a Growing Economy (EDGE) program.
Additionally, construction is progressing on a $70 million expansion of the AbbVie Bioresearch Center in Worcester, Mass., which serves as a center of excellence for biologics R&D and manufacturing. The company has also agreed to participate in TrumpRx.gov, a direct-to-patient platform that will enable millions of Americans to purchase medicines at reduced rates.
